Liu Z et al. identified a correlation between upregulated expression of B7H4, tumour mutation burden (TMB) and higher responsiveness to anti-PD-L1 therapy in bladder cancer patients. This evidence concerns the gene VTCN1 and urinary bladder carcinoma.